Clinical outcomes and toxicity of proton beam therapy for advanced cholangiocarcinoma

Radiation Oncology

Tomio Inoue⁴  Masaharu Hata⁴  Nobukazu Fuwa³  Masao Murakami¹  Masato Hareyama²  Yasuhiro Kikuchi²  Iwao Tsukiyama²  Takahiro Kato²  Yusuke Azami²  Yojiro Ishikawa²  Motohisa Suzuki²  Kanako Takayama²  Akinori Takada²  Tatsuya Nakamura¹  Chiyoko Makita² 

[1] Department of Radiology, Graduate School of Medicine, Dokkyo Medical University, 880 Kitakobayashi, Mibu-machi, 321-0293 Shimotsuga, Tochigi, Japan;Department of Radiation Oncology, Southern Tohoku Proton Therapy Center, 7-172, Yatsuyamada, 963-8052 Koriyama, Fukushima, Japan;Hyogo ion beam Medical Center, 1-2-1 Koto, Shingu, 679-5165 Tatsuno, Hyogo, Japan;Department of Radiology, Graduate School of Medicine, Yokohama City University, 3-9 Fukuura, 236-0004 Kanazawa-ku, Yokohama, Japan

关键词: Gastrointestinal toxicity;    Cholangitis;    Chemoradiotherapy;    Proton beam therapy;    Cholangiocarcinoma;   

Others  :  814996
DOI  :  10.1186/1748-717X-9-26

 received in 2013-03-18, accepted in 2014-01-09,  发布年份 2014

【 摘 要 】

Background

We examined the efficacy and toxicity of proton beam therapy (PBT) for treating advanced cholangiocarcinoma.

Methods

The clinical data and outcomes of 28 cholangiocarcinoma patients treated with PBT between January 2009 and August 2011 were retrospectively examined. The Kaplan–Meier method was used to estimate overall survival (OS), progression-free survival (PFS), and local control (LC) rates, and the log-rank test to analyze the effects of different clinical and treatment variables on survival. Acute and late toxicities were assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0.

Results

The median age of the 17 male and 11 female patients was 71 years (range, 41 to 84 years; intrahepatic/peripheral cholangiocarcinoma, n = 6; hilar cholangiocarcinoma/Klatskin tumor, n = 6; distal extrahepatic cholangiocarcinoma, n = 3; gallbladder cancer, n = 3; local or lymph node recurrence, n = 10; size, 20–175 mm; median 52 mm). The median radiation dose was 68.2 Gy (relative biological effectiveness [RBE]) (range, 50.6 to 80 Gy (RBE)), with delivery of fractions of 2.0 to 3.2 Gy (RBE) daily. The median follow-up duration was 12 months (range, 3 to 29 months). Fifteen patients underwent chemotherapy and 8 patients, palliative biliary stent placement prior to PBT. OS, PFS, and LC rates at 1 year were 49.0%, 29.5%, and 67.7%, respectively. LC was achieved in 6 patients, and was better in patients administered a biologically equivalent dose of 10 (BED10) > 70 Gy compared to those administered < 70 Gy (83.1% vs. 22.2%, respectively, at 1 year). The variables of tumor size and performance status were associated with survival. Late gastrointestinal toxicities grade 2 or greater were observed in 7 patients <12 months after PBT. Cholangitis was observed in 11 patients and 3 patients required stent replacement.

Conclusions

Relatively high LC rates after PBT for advanced cholangiocarcinoma can be achieved by delivery of a BED10 > 70 Gy. Gastrointestinal toxicities, especially those of the duodenum, are dose-limiting toxicities associated with PBT, and early metastatic progression remains a treatment obstacle.

【 授权许可】

   
2014 Makita et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

【 参考文献 】

• [1]Parkin DM, Whelan SL, Ferlay J, et al.: Cancer incidence in five continents, volumes I to VIII. IARC Cancer Base 2005, 7:258-269.
• [2]Erickson BA, Nag S: Biliary tree malignancies. J Surg Oncol 1998, 67:203-210.
• [3]Blumgart LH, Hadjis NS, Bnjamin IS, et al.: Surgical approaches to cholangiocarcinoma at confluence of hepatic ducts. Lancet 1984, 1:66-70.
• [4]Farley DR, Weaver AL, Nagorney DM, et al.: “Natural history” of unresected cholangiocarcinoma: patient outcome after noncurative intervention. Mayo Clin Proc 1995, 70:425-429.
• [5]Shinohara ET, Mitra N, Guo M, et al.: Radiotherapy is associated with improved survival in adjuvant and apalliativea treatment of extrahepatic cholangiocarcinomas. Int J Radat Oncol Biol Phys 2009, 74:1191-1198.
• [6]Fuller CD, Wang SJ, Choi M, et al.: Multimodality therapy for locoregional extrahepatic cholangiocarcinoma. Cancer 2009, 115:5175-5183.
• [7]Schoenthaler R, Phillips T, Castro J: Carcinoma of the extrahepatic bile ducts: UCSF experience. Ann Surg 1994, 219:267-274.
• [8]Zgodzinski W, Espat NJ: Radiofrequency ablation for incidentally identified primary intrahepatic cholangiocarcinoma. World J Gastroenterol 2005, 11:5239-5240.
• [9]Herber S, Otto G, Schneider J, et al.: Transcatheter arterial chemoembolization (TACE) for inoperable intrahepatic cholangiocarcinoma. Cardiovasc Intervent Radiol 2007, 30:1156-1165.
• [10]Fuller CD, Dang ND, Wang SJ, et al.: Image-guided intensity-modulated radiotherapy (IG-IMRT) fore biliary adenocarcinomas: initial clinical results. Radio and Oncol 2009, 92:249-254.
• [11]Polistina FA, Guglielmi R, Baiocchi C: Chemoradiation treatment with gemcitabine plus stereotactic body radiotherapy for unresectable, non-metastatic locally advanced hilar cholangiocarcinoma. Results of a five year experience. Radio and Oncol 2011, 99:120-123.
• [12]Alden ME, Mohiduddin M: The impact of radiation dose in combined external beam and intraluminal Ir-192 brachytherapy for bile duct cancer. Int J Radat Oncol Biol Phys 1994, 28:945-951.
• [13]Valek V, Kysela P, Kala Z, et al.: Brachytherapy and percutaneous stenting in the treatment of cholangiocarcinoma: a prospective randomized study. Euro J Radio 2007, 62:175-179.
• [14]Crane CH, Macdonald KO, Vauthey JN, et al.: Limitations of conventional doses of chemoradiation for unresectable biliary cancer. Int J Radat Oncol Biol Phys 2002, 53:969-974.
• [15]Kopelson G, Harsiadis L, Tretter P, et al.: The role of radiation therapy in cancer of extrahepatic biliary system: an analysis of thirteen patients and a review of the literature of the effectiveness of surgery, chemotherapy and radiotherapy. Int J Radat Oncol Biol Phys 1977, 2:883-894.
• [16]Deodato F, Clement G, Carlo G, et al.: Chemoradiation and brachytherapy in biliary tract carcinoma: long-term results. Int J Radat Oncol Biol Phys 2006, 64:483-488.
• [17]Ben-David MA, Griffith KA, Abu-Isa E, et al.: External-beam radiotherapy for localized extrahepatic cholangiocarcinoma. Int J Radat Oncol Biol Phys 2006, 66:772-779.
• [18]Emami B, Lyman J, Brown A, et al.: Tolerance of normal tissue to therapeutic irradiation. Int J Radat Oncol Biol Phys 1991, 21:109-122.